Corcept Therapeutics
CORT | NASDAQ
$80.73
-$0.39 (-0.48%)
Nov 2, 2026, 11:59 AM ET · Market open
Market Data
Market Cap $8.73B
Enterprise Value $8.47B
Beta 0.45
Average Volume 1.21M
Shares Outstanding (Diluted) 118.39M
Shares Change YoY -1.74%
Institutional Ownership 79.26%
Exchange NASDAQ
ISIN US2183521028
Price Performance
Price Change 1M -30.5%
Price Change 3M -28.4%
Price Change 6M 56.5%
Price Change YTD 132.0%
Price Change 1Y 8.8%
Price Change 3Y 215.1%
Price Change 5Y 342.6%
1M CAGR (ann.) -26.4%
1Y CAGR (ann.) 12.6%
5Y CAGR (ann.) 34.1%
All-Time CAGR 27.9%
Valuation
PE Ratio 193.07
Forward PE 20.00
PEG Ratio -2.66
Forward PEG 1.38
PS Ratio 10.55
Forward PS 5.60
PB Ratio 12.42
P/FCF Ratio 81.98
P/Adj. FCF Ratio 74.16
P/OCF Ratio 77.97
EV/Sales 10.19
EV/EBIT 321.09
EV/EBITDA 294.10
EV/FCF 79.19
Earnings Yield 0.5%
FCF Yield 1.2%
Adj. FCF Yield 1.4%
Financial Health
Net Cash $298.78M
Total Debt $9.42M
Cash & Short-Term Investments $308.2M
Total Assets $888.7M
Current Ratio 2.86
Quick Ratio 2.77
Debt / Equity Ratio 0.01
Debt / EBITDA 0.33
Debt / FCF 0.09
OCF / Debt 11.64
Interest Coverage 0.00
Altman Z-Score 31.21
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 98.3%
Operating Profit Margin 0.8%
EBITDA Margin 3.5%
Net Profit Margin 6.6%
FCF Margin 12.9%
Adj. FCF Margin 14.2%
SBC / Revenue -1.4%
SBC Impact (per share) -10.5%
Returns
Return on Assets 6.2%
Return on Equity 8.4%
Return on Invested Capital 0.9%
Return on Capital Employed 0.9%
Return on Tangible Assets 6.2%
Historical Growth (CAGR)
Revenue CAGR 3Y 24.7%
Revenue CAGR 5Y 19.4%
Revenue CAGR 10Y 29.2%
EPS CAGR 3Y -20.3%
EPS CAGR 5Y -11.2%
EPS CAGR 10Y 43.3%
FCF CAGR 3Y -7.4%
FCF CAGR 5Y -4.4%
FCF CAGR 10Y 26.8%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 5
EPS Growth Next 3Y 153.7%
Revenue Growth Next 3Y 43.8%
Earnings Date Nov 3, 2026
EPS Estimate (next Q) $0.79
EPS Growth Est (next Q) 396.3%
Revenue Est (next Q) $323.9M
Revenue Growth Est (next Q) 56.0%
Fair Value Estimates
Graham Number $7.96
Graham Upside -90.2%
Lynch Fair Value $2.10
Lynch Upside -97.4%
Price Target $125.33
Price Target Upside 54.6%
Cash Flow
Operating Cash Flow $109.7M
Free Cash Flow $106.92M
Adj. Free Cash Flow $118.19M
FCF Per Share $1.01
OCF Per Share $1.04
OCF/S Ratio 13.2%
Income Statement
Revenue $830.81M
Gross Profit $816.73M
Operating Income $6.41M
EBITDA $28.79M
Net Income $54.9M
EPS (Diluted) $0.42
Revenue / Employee $1.14M
Profit / Employee $75.2K
Employees 730
Add to Watchlist
Select watchlists to add or remove CORT